Teva and its partner Sanofi say 47.8% of patients with ulcerative colitis who received a high dose of their drug duvakitug ...
City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the United States with its National Medical Center named top 5 in the nation for cancer by U.S. News ...
As part of the ongoing Human Cell Atlas project, researchers mapped 1.6 million cells in the gastrointestinal tract. Here’s ...
Teva Pharmaceuticals and Sanofi announced positive results in a Phase 2b trial of their drug for ulcerative colitis and Crohn ...
The search for effective therapies in ulcerative colitis, a chronic inflammatory condition affecting the colon and rectum with a relapsing–remitting course, has been a long and challenging journey, ...
Phase 2 results in inflammatory bowel disease hinted the therapy could be more potent than similar medicines from Merck and ...
MT Newswires on MSN12h
Teva, Sanofi Say Inflammatory Bowel Disease Drug Study Meets Primary EndpointsUS affiliate and partner Sanofi (SNY) said Tuesday that a phase 2b study of Teva's investigational duvakitug drug to treat ulcerative colitis and Crohn's disease met its primary endpoints. Ulcerative ...
16hon MSN
Dr. Parul Shukla said he’s recently operated on multiple patients in their 40s, and some of them otherwise appear to be in ...
These 1,395 physicians, nominated by their peers, are the right prescription for what ails you.
Crohn disease location, particularly ileal predominance, is associated with specific treatment patterns, such as more biologic therapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback